JP2007517885A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517885A5
JP2007517885A5 JP2006549374A JP2006549374A JP2007517885A5 JP 2007517885 A5 JP2007517885 A5 JP 2007517885A5 JP 2006549374 A JP2006549374 A JP 2006549374A JP 2006549374 A JP2006549374 A JP 2006549374A JP 2007517885 A5 JP2007517885 A5 JP 2007517885A5
Authority
JP
Japan
Prior art keywords
composition
adamantane
component
eye
neuroprotective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006549374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517885A (ja
Filing date
Publication date
Priority claimed from US10/752,125 external-priority patent/US20050147584A1/en
Priority claimed from US10/941,272 external-priority patent/US20050031652A1/en
Application filed filed Critical
Publication of JP2007517885A publication Critical patent/JP2007517885A/ja
Publication of JP2007517885A5 publication Critical patent/JP2007517885A5/ja
Withdrawn legal-status Critical Current

Links

JP2006549374A 2004-01-05 2005-01-04 眼に投与するためのメマンチンおよびポリアニオン性ポリマーを含む組成物 Withdrawn JP2007517885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/752,125 US20050147584A1 (en) 2004-01-05 2004-01-05 Compositions and methods comprising memantine and polyanionic polymers
US10/941,272 US20050031652A1 (en) 2003-02-25 2004-09-14 Compositions and methods comprising memantine and polyanionic polymers
PCT/US2005/000249 WO2005067891A1 (en) 2004-01-05 2005-01-04 Compositions comprosing memantine and polyanionic polymers for administration to the eye

Publications (2)

Publication Number Publication Date
JP2007517885A JP2007517885A (ja) 2007-07-05
JP2007517885A5 true JP2007517885A5 (cg-RX-API-DMAC10.html) 2008-02-21

Family

ID=34798997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006549374A Withdrawn JP2007517885A (ja) 2004-01-05 2005-01-04 眼に投与するためのメマンチンおよびポリアニオン性ポリマーを含む組成物

Country Status (7)

Country Link
US (1) US20050031652A1 (cg-RX-API-DMAC10.html)
EP (1) EP1701700A1 (cg-RX-API-DMAC10.html)
JP (1) JP2007517885A (cg-RX-API-DMAC10.html)
AU (1) AU2005204365A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0506689A (cg-RX-API-DMAC10.html)
CA (1) CA2552521A1 (cg-RX-API-DMAC10.html)
WO (1) WO2005067891A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
JP2002182418A (ja) * 2000-12-11 2002-06-26 Konica Corp 画像形成方法、画像形成装置
US20080033053A1 (en) * 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
JP2008507588A (ja) * 2004-07-26 2008-03-13 アラーガン、インコーポレイテッド 眼の病態を処置する方法
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
SI2074123T1 (sl) 2006-10-16 2013-03-29 Bionomics Limited Nove anksiolitične spojine
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2008098027A2 (en) * 2007-02-06 2008-08-14 Allergan, Inc. Treatment of ischemic retinal conditions with memantine
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
WO2012116415A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
CN103649086A (zh) 2011-05-12 2014-03-19 生态学有限公司 制备萘啶的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5008242A (en) * 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5691316A (en) * 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
AU761824B2 (en) * 1998-10-27 2003-06-12 Alcon Laboratories, Inc. Treatment of disorders of the outer retina
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
CA2368242A1 (en) * 1999-03-12 2000-09-21 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
US6482854B1 (en) * 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
SK282717B6 (sk) * 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US6761694B2 (en) * 2001-12-13 2004-07-13 Allergan, Inc. Methods for measuring retinal damage
US6982079B2 (en) * 2002-04-26 2006-01-03 Allergan, Inc. Compositions for treating hyperemia
EP1654002B2 (en) * 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes

Similar Documents

Publication Publication Date Title
TWI620569B (zh) 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
WO2007108541A1 (ja) キサンタンガムおよびブドウ糖を含有する眼科用組成物
WO2010004435A3 (en) Ph specific solutions of sodium mycophenolic acid for the treatment of eye disorders
HU197840B (en) Process for producing synergic pharmaceutical compositions comprising amantadin and selegilin
JP2009524692A5 (cg-RX-API-DMAC10.html)
NZ602445A (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
JP6842794B2 (ja) 皮膚外用製剤
JP2023168547A (ja) 眼科組成物
RU99121654A (ru) Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки
JP4752987B2 (ja) 外用剤組成物
JP2018505901A5 (cg-RX-API-DMAC10.html)
CN113876788B (zh) 红景天苷水凝胶制剂及其制备方法和应用
JP2023550393A (ja) セチリジン及びトコフェルソランを含む眼科用組成物
JP2003073303A (ja) 眼局所用液剤の清涼化作用の持続方法
TWI712429B (zh) 水性醫藥組成物
DE69424679T2 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
JP2002308764A (ja) 眼科用医薬組成物
CN104994839A (zh) 局部眼用镇痛剂
JP2006176501A (ja) 眼科用剤
WO2005016336A1 (en) Method and composition for treating burned skin
RU2006101150A (ru) Композиции нестероидных противовоспалительных средств для лечения патологического ангиогенеза глаз
JP2022543598A5 (cg-RX-API-DMAC10.html)
JP5957517B2 (ja) 結膜弛緩症治療用の点眼薬
JP7778396B2 (ja) シロスタゾールを含む組成物の脳血管疾患への応用
JP7699855B2 (ja) シロスタゾールを含む組成物の脳血管疾患の治療薬の調製への応用